Compare AbCellera Biologics Inc (ABCL) vs Halliburton Company (HAL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Halliburton Company — how do they compare? AbCellera Biologics Inc trades at $7.17 (market cap $2.35B), while Halliburton Company trades at $34.73 (market cap $28.23B). The key difference: Halliburton Company is far larger — about 12× AbCellera Biologics Inc's market cap, and Halliburton Company pays a 2.01% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | HAL | |
|---|---|---|
Market Cap | $2.35B | $28.23B |
Sector | Health | Energy |
52-Week High | $8.12 | $42.98 |
52-Week Low | $2.78 | $20.50 |
Enterprise Value | $1.99B | $34.31B |
Dividend Yield | — | 2.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
Halliburton (HAL) trades at $33.79, up 2.52% today, with a bearish technical signal despite recent earnings beats. The company maintains solid fundamentals with a P/E of 18.23 and ROE of 14.56%, though 2025 revenue declined to $22.18B. Recent news highlights digital transformation partnerships and upcoming Q2 2026 earnings, while analyst consensus remains strongly bullish with a $44.22 price target.
HAL presents a compelling value opportunity with 30% upside to consensus target, supported by consistent earnings outperformance and strategic digital initiatives. Key risks include oil price volatility and competitive pressures in energy services. The stock's current discount to analyst targets and strong institutional support suggest potential for recovery despite near-term technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Halliburton Company
Halliburton is one of the three largest oilfield service firms in the world, offering superior expertise in a number of business lines, including completion fluids, wireline services, cementing, and countless others. It's the number one pressure pumper in North America, and has been a leading innovator in hydraulic fracturing over the last two decades.
Read more on HAL →
